Abstract: In some aspects, the present disclosure provides pharmaceutical compositions comprising particles, wherein individual particles of the composition comprise a combination of two or more active pharmaceutical ingredients selected from: (A) nintedanib; (B) pirfenidone; and/or (C) mycophenolic acid. These compositions may be formulated for administration via inhalation. In some aspects, the present disclosure provides methods for preparing the pharmaceutical compositions of the present disclosure and methods of treating or preventing a disease or disorder using the pharmaceutical compositions of the present disclosure.

Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

Abstract: The present invention includes compositions and methods for making and using a rapid dissolving, high potency, substantially amorphous nanostructured aggregate for pulmonary delivery of tacrolimus and a stabilizer matrix comprising, optionally, a polymeric or non-polymeric surfactant, a polymeric or non-polymeric saccharide or both, wherein the aggregate comprises a surface area greater than 5 m2/g as measured by BET analysis and exhibiting supersaturation for at least 0.5 hours when 11-15-times the aqueous crystalline solubility of tacrolimus is added to simulated lung fluid.

Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.

Abstract: Dry powder compositions comprising biologically active polynucleotide molecules and methods for the manufacture of such dry powders are provided. In some aspects, dry powders of the embodiment comprise expressible or regulatory (e.g., siRNA) polynucleotide molecules complexed with nanoparticles. Dry powders comprising viable virus and bacteria are also provided.

Abstract: Pharmaceutical compositions which contain at less than 10% of an excipient and are presented as nanoaggregates are described herein. These pharmaceutical compositions have been shown to exhibit improved properties such as improved aerosolizability and aerodynamic performance. Also provided herein are methods of preparing the pharmaceutical compositions disclosed herein and use thereof.

Abstract: Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI).

Abstract: The present disclosure provides pharmaceutical compositions of niclosamide that may be administered either orally or by inhalation. These compositions may allow the achievement of a therapeutically effective dose of niclosamide to the lungs or the gastrointestinal tract. These compositions may be used to treat one or more diseases or disorders such as a viral infection or cancer.

Abstract: The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm?1 area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30° C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm?1.

Abstract: Provided herein are compositions comprising caveolin-1 (Cav-1) peptides. Further provided are methods of using the Cav-1 peptides for the treatment of lung infections or acute or chronic lung injury, particularly lung fibrosis.

Abstract: Methods and composition for delivery of enzymes to a subject's airway. In some aspects, nebulized composition of enzymes, such as plasminogen activators are provided. In further aspects perfluorocarbon compositions comprising enzymes, such as plasminogen activators are provided. Compositions may, in some aspects, be used for the treatment of lung infections or acute lung injury, such as inhalational smoke induced acute lung injury (ISALI).

Abstract: Compositions and methods of preparing amorphous drug formulations through hot melt extrusion which result in decreased decomposition of the desired drug are provided herein. Also provided are methods and compositions which further comprise a pharmaceutically acceptable thermoplastic polymer. In some embodiments, these compositions comprise a therapeutically active agent which is only sparingly soluble in water.

Abstract: Disclosed herein are compositions and methods for reducing fluid loss in a well bore. Also disclosed herein are methods for wellbore strengthening and increasing the integrity of the borehole of an oil or gas well. In particular, disclosed are methods for artificially increasing the temperature of a subsurface formation in the wellbore to increase the apparent wellbore strength.

Abstract: The present disclosure relates to pharmaceutical formulations including a weakly basic drug and an ionic polymer in an amorphous solid dispersion, as well as methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations.

Abstract: Methods of producing substantially amorphous pharmaceutical formulations by hot melt extrusion (HME) are provided. In some aspects, the methods can be performed at lower temperatures than are typically required for HME. Pharmaceutical formations produced by these methods are also provided.

Abstract: Disclosed herein arc compositions and methods for reducing fluid loss in a well bore. This invention relates to methods for wellbore strengthening and increasing the integrity of the borehole of an oil or gas well. In particular, the invention relates to methods for artificially increasing the temperature of a subsurface formation in the wellbore to increase the apparent wellbore strength. The mechanism for accomplishing this revolves around increasing fracture propagation pressure by actively manipulating thermal wellbore stresses.

Abstract: The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm?1 area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30° C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm?1.

Abstract: The present invention includes compositions and methods for treating and delivering medicinal formulations using an inhaler. The composition includes a space filled flocculated suspension having one or more flocculated particles of one or more active agents and a hydrofluoroalkane propellant. A portion of the one or more flocculated particles is templated by the formation of hydrofluoroalkane droplets upon atomization and the templated floc compacts upon the evaporation of the hydrofluoroalkane propellant to form a porous particle for deep lung delivery.

Abstract: Pharmaceutical compositions for improving the solubility and dissolution of poorly soluble drugs, which contain a therapeutic agent, a pharmaceutically acceptable polymer, and a mesoporous carrier. These pharmaceutical compositions have been prepared by thermal processes and fusion-based high energy mixing processes that do not require external heat input to obtain a composition that shows improved properties.

Abstract: Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can he further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.